These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35673960)

  • 21. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine.
    Maher DI; Hogarty D; Ben Artsi E
    Orbit; 2023 Dec; 42(6):630-634. PubMed ID: 35499172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature.
    Virgilio E; Tondo G; Montabone C; Comi C
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Lu X; Masuda S; Horlad H; Katoh T
    Vaccine; 2023 Aug; 41(35):5090-5096. PubMed ID: 37455163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
    J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Clinical Course of New-Onset Ocular Myasthenia Gravis Caused by Pfizer-BioNTech COVID-19 Vaccine.
    Su WY; Lu CJ
    Acta Neurol Taiwan; 2023 Dec; 32(4)():218-222. PubMed ID: 37723915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature.
    Ramdas S; Hum RM; Price A; Paul A; Bland J; Burke G; Farrugia M; Palace J; Storrie A; Ho P; Standing E; Lilleker JB; Jungbluth H
    Neuromuscul Disord; 2022 Oct; 32(10):785-789. PubMed ID: 36130855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
    Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
    Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Immunogenicity of Additional SARS-CoV-2 Vaccinations in a Patient With Myasthenia Gravis on Mycophenolate: A Case Report.
    McNeish BL; Colletti RB; Hehir MK
    J Clin Neuromuscul Dis; 2022 Dec; 24(2):113-114. PubMed ID: 36409346
    [No Abstract]   [Full Text] [Related]  

  • 31. COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined.
    Kim S; Eun MY; Seok HY
    Neurol Sci; 2023 May; 44(5):1503-1504. PubMed ID: 36808584
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
    Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 vaccination and myasthenia gravis.
    Arbel A; Bishara H; Barnett-Griness O; Cohen S; Najjar-Debbiny R; Gronich N; Auriel E; Saliba W
    Eur J Neurol; 2023 Dec; 30(12):3989-3990. PubMed ID: 37797299
    [No Abstract]   [Full Text] [Related]  

  • 35. COVID-19 vaccination and myasthenia gravis.
    Kleebayoon A; Wiwanitkit V
    Eur J Neurol; 2023 Dec; 30(12):3988. PubMed ID: 37797298
    [No Abstract]   [Full Text] [Related]  

  • 36. Traditional Chinese medicine auricular point acupressure for the relief of pain, fatigue, and gastrointestinal adverse reactions after the injection of novel coronavirus-19 vaccines: a structured summary of a study protocol for a multicentre, three-arm, single-blind, prospective randomized controlled trial.
    Fu Q; Xie H; Zhou L; Li X; Liu Y; Liu M; Wang C; Wang X; Wang Z; Tang J; Xiao H; Xiao Z; Zhou J; Feng C; Wang L; Ao Z; Chen X; Su C; Wu X; Zhao M; Hu S; Lin H; Huang J; Xu G; Zhang Q; Jiang L
    Trials; 2021 Feb; 22(1):162. PubMed ID: 33632286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to achieve a patient acceptable symptom state in myasthenia gravis.
    Martinez-Harms R; Barnett C; Bril V
    Front Neurol; 2023; 14():1187189. PubMed ID: 37396757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Side effects after COVID-19 vaccinations among residents of Poland.
    Andrzejczak-Grządko S; Czudy Z; Donderska M
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study.
    Rogers A; Rooke E; Morant S; Guthrie G; Doney A; Duncan A; Mackenzie I; Barr R; Pigazzani F; Zutis K; MacDonald TM
    BMJ Open; 2022 Jun; 12(6):e060583. PubMed ID: 35649591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.